Vivo Bio Tech Limited will hold a board meeting on May 29, 2026, to consider and approve the audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The meeting, scheduled at the company's registered office, will also deliberate on the amalgamation of Shri Shri Resorts Private Limited with and into Vivo Bio Tech Limited under Sections 230 to 232 and other relevant provisions of the Companies Act, 2013, and SEBI Listing Regulations.

Agenda for the Board Meeting

The primary focus of the meeting is the approval of the financial results for Q4FY26 and the full fiscal year. Additionally, the board will evaluate the proposed merger, which involves Shri Shri Resorts Private Limited as the transferor company and Vivo Bio Tech Limited as the transferee company.

Trading Window Closure

In view of the upcoming board meeting, the trading window for Vivo Bio Tech Limited will remain closed for all directors, promoters, designated employees, and specified connected persons until May 31, 2026. This measure is intended to prevent the misuse of unpublished price-sensitive information.

Key Details

The board's decisions on the financial results and the proposed amalgamation will be subject to regulatory approvals and disclosures.

Vivo Bio Tech Limited has filed its compliance report with BSE Limited regarding the status of physical share transfer requests for March 2026, showing zero activity across all parameters under the SEBI special re-lodgement window.

Regulatory Compliance Report

The report was submitted on April 13, 2026, by Company Secretary A V Kiran in compliance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. This circular established a special window for the re-lodgement of transfer requests pertaining to physical shares.

Transfer Request Status for March 2026

The detailed status report prepared by Aarthi Consultants Private Limited, the company's registrar and share transfer agent, shows complete absence of physical share transfer activity:

Registrar and Transfer Agent Details

Aarthi Consultants Private Limited serves as the Category I Registrars & Share Transfer Agents for Vivo Bio Tech Limited. The company holds SEBI Registration No. INR000000379 and operates under CIN: U74140TG1992PTC014044. The compliance report was signed by Jagan Mohan Gobburi, Compliance Officer at Aarthi Consultants Private Limited, on April 6, 2026.

SEBI Circular Implementation

The SEBI circular dated January 30, 2026, requires companies to report monthly on the status of physical share transfer re-lodgement requests. This regulatory measure aims to facilitate the transfer of physical shares through a designated special window, with companies required to maintain detailed records and submit regular status updates to stock exchanges.